This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MediciNova Receives A Notice Of Allowance For A Method Of Treating Drug Addiction Or Dependence

SAN DIEGO, March 9, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of Ibudilast for the treatment of drug addiction or drug dependence or withdrawal syndrome. Ibudilast, aka MN-166 or AV411, is the company's lead drug candidate for certain neurological conditions, including neuropathic pain, drug addiction and progressive multiple sclerosis.

The patent, once issued, covers the use of ibudilast for therapeutic administration alone or in combination with other drugs for the treatment of opioid addiction, dependence, or withdrawal syndrome. Ibudilast is a non-opioid inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterases-4 and -10 (PDEs-4, -10) and has been shown to reduce glial cell activation. Such a cellular action has been experimentally linked to certain neurochemical and behavioral changes associated with addiction to drugs like opioids and methamphetamine. The patent application is based upon research by Linda Watkins, Ph.D., and colleagues at University of Colorado, Boulder, and Kirk Johnson, Ph.D., Chief Scientific Officer, at MediciNova. As mentioned above, the allowed claims include a method of treating an opioid withdrawal syndrome, which is sometimes observed in patients who stop or reduce their use of opioids like morphine and oxycodone (i.e., Vicodin®), and the reduction of associated glial cell activation. The allowed claims also cover the use of ibudilast in combination with buprenorphine, itself an opioid, which is approved (i.e., Suboxone®) for treating opioid dependence.

Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, noted that "We are very pleased to receive notice of this patent allowance for ibudilast in drug addiction, especially on the heels of our recent announcement of encouraging preliminary clinical trial results in morphine withdrawal and analgesia." Dr. Iwaki added that "Positive progress in our MN-166 program along with our ongoing phase 2 asthma exacerbation trial with another of our lead drug candidates, MN-221, speaks to our pipeline quality."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs